Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is now considered a standard procedure for the treatment of several hematologic malignancies. Indeed, over several decades, allogeneic HSCT has shown and confirmed a strong graft versus leukemia (GvL) effect. More recently, bispecific monoclonal antibodies, CAR-T cells and check point inhibitors have been tested in combination with allogeneic HSCT, with the aim to improve the therapeutic efficacy of transplantation.
In the present Research Topic we aim to provide a comprehensive overview of the current studies assessing the graft versus leukemia effect after HSCT transplantation, focusing on the mechanism of the immune response against cancer cells. This will include both studies on animal models and clinical data from patients. We will be discussing the use of HSTC in different malignancies, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelofibrosis and myelodisplastic disease (MDS). We will also welcome studies combining allogeneic HSCT with other immune-therapies, such as antibodies, CAR-T cells and check point inhibitors.
We welcome the submission of Original Research, Review Articles and Clinical Trial, covering the following topics:
• Graft versus leukemia (GvL): animal models
• Graft versus leukemia (GvL): clinical data
• Stem cell source and GvL: Bone Marrow (BM), Peripheral Blood (PB), Cord Blood (CB)
• Allogeneic HSCT for the treatment of hematopoietic malignancies (AML, ALL, MDS and Myelofibrosis): who, when and how
• Efficacy of therapies testing allogeneic HSCT in combination with CAR-T cells or bispecific monoclonal antibodies.
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is now considered a standard procedure for the treatment of several hematologic malignancies. Indeed, over several decades, allogeneic HSCT has shown and confirmed a strong graft versus leukemia (GvL) effect. More recently, bispecific monoclonal antibodies, CAR-T cells and check point inhibitors have been tested in combination with allogeneic HSCT, with the aim to improve the therapeutic efficacy of transplantation.
In the present Research Topic we aim to provide a comprehensive overview of the current studies assessing the graft versus leukemia effect after HSCT transplantation, focusing on the mechanism of the immune response against cancer cells. This will include both studies on animal models and clinical data from patients. We will be discussing the use of HSTC in different malignancies, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelofibrosis and myelodisplastic disease (MDS). We will also welcome studies combining allogeneic HSCT with other immune-therapies, such as antibodies, CAR-T cells and check point inhibitors.
We welcome the submission of Original Research, Review Articles and Clinical Trial, covering the following topics:
• Graft versus leukemia (GvL): animal models
• Graft versus leukemia (GvL): clinical data
• Stem cell source and GvL: Bone Marrow (BM), Peripheral Blood (PB), Cord Blood (CB)
• Allogeneic HSCT for the treatment of hematopoietic malignancies (AML, ALL, MDS and Myelofibrosis): who, when and how
• Efficacy of therapies testing allogeneic HSCT in combination with CAR-T cells or bispecific monoclonal antibodies.
